Refining HRD-Guided PARP Inhibitor Use in Advanced Ovarian Cancer
At Great Debates Solid Tumors in Miami, Florida, Angeles Secord, MD, from Duke University, Durham North Carolina, discusses the evolving role of homologous recombination deficiency (HRD) as a biomarker and the need for improved patient selection in advanced ovarian cancer.
Dr Secord highlights that while HRD is a valuable biomarker, refinement is needed to better guide PARP inhibitor use, with clear benefit in BRCA-mutated patients, more limited benefit in HRD-positive/BRCA–wild-type disease, and minimal utility in HR-proficient populations.
Source:
Secord A. Front-line maintenance therapy for ovarian cancer: It is a PARPi and bevacizumab world – Don’t fix what is not broken vs we can do better than HRD – Opportunities for new biomarkers and agents to improve outcomes. Presented at Great Debates - Solid Tumors; Miami, Florida. March 14-15, 2026.
